An APC for every occasion: induction and expansion of human Ag-specific CD4 and CD8 T cells using cellular and non-cellular APC

References

• O'Reilly RJ, Small TN, Papadopoulos E et al. Biology and adoptive cell therapy of Epstein— Barr virus-associated lympho-proliferative disorders in recipients of marrow allografts. Immunol Rev 1997;157:195–216.
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Ruler N et al. Infusion of cytomegalovirus(CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99:3916–22.
   PubMed Web of Science ®Google Scholar
• Sun Q, Burton R, Reddy Vet al. Safety of allogeneic Epstein—Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br 7 Haematol 2002;118: 799— 808.
   Google Scholar
• Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein— Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549— 55.
   Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regressionand autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850–4.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patientswith metastatic melanoma with autologous rumor-infiltrating lymphocytes and interleukin 2. 7Natl Cancer Inst 1994;86:1159–66.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Witmer-Pack M, Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993;329:1–9.
   PubMedGoogle Scholar
• Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10–6.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus inter-leukin 4 and downregulated by tumor necrosis factor alpha. y Exp Med 1994;179:1109–18.
   PubMed Web of Science ®Google Scholar
• Young JW, Szabolcs P, Moore MA. Identification of dendritic cellcolony-forming units among normal human CD34± bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/ macrophage colony-stimulating factor and tumor necrosis factor alpha. y Exp Med 1995;182: 1111–9.
   PubMed Web of Science ®Google Scholar
• Caux C, Vanbervliet B, Massacrier C et al. CD34± hemato-poietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSFTNF alpha. y Exp Med 1996;184:695–706.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control ofimmunity. Nature 1998;392:245–52.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M et al. Ex vivo induction ofmultiple myeloma-specific cytotoxic T lymphocytes. Blood 2003;102:1435–42.
   PubMed Web of Science ®Google Scholar
• Oelke M, Moehrle U, Chen JL et al. Generation and purificationof CD8± melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res 2000;6:1997–2005.
   PubMed Web of Science ®Google Scholar
• Schnurr M, Galambos P, Scholz C et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 2001;61:6445–50.
   PubMed Web of Science ®Google Scholar
• Melenhorst JJ, Solomon SR, Zhao L et al. Up to 45% transduction of human G-CSF mobilized peripheral blood CD34 cells following a single exposure to a retroviral vector facilitates efficient generation of gene-modified dendritic cells for immunotherapy. Blood 2003;102:2946.
   Google Scholar
• Herr W, Ranieri E, Olson Wet al. Mature dendritic cells pulsedwith freeze- thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4( +) and CD8(± ) T lymphocyte responses. Blood 2000;96:1857–64.
   PubMed Web of Science ®Google Scholar
• Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int y Cancer 2001;91:749–56.
   Google Scholar
• Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol 1998;16:201–23.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685–711.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol2004;4:499–511.
   PubMed Web of Science ®Google Scholar
• Cella M, Engering A, Pinet Vet al. Inflammatory stimuli induceaccumulation of MHC class II complexes on dendritic cells. Nature 1997;388:782–7.
   PubMed Web of Science ®Google Scholar
• Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunio, 1998;8:89–95.
   PubMed Web of Science ®Google Scholar
• Gett AV, Sallusto F, Lanzavecchia A et al. T cell fitness determined by signal strength. Nat Immunol 2003;4:355–60.
   PubMed Web of Science ®Google Scholar
• Cella M, Scheidet ter D, Palmer-Lehmann K et al. Ligation ofCD40 on dendritic cells triers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. y Exp Med 1996;184:747–52.
   PubMed Web of Science ®Google Scholar
• Behrens G, Li M, Smith CM et al. Helper T cells, dendritic cellsand CTL Immunity. Immunol Cell Biol 2004;82:84–90.
   Google Scholar
• Bennett SR, Carbone FR, Karamalis F et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478–80.
   PubMed Web of Science ®Google Scholar
• Ridge JP, Di Rosa F', Matzinger P. A conditioned dendritic cellcan be a temporal bridge between a CD4± T-helper and a T-killer cell. Nature 1998;393:474–8.
   PubMed Web of Science ®Google Scholar
• Schoenberger SP, Toes RE, van der Voort El et al. T-cell help forcytotoxic T lymphocytes is mediated by CD40- CD4OL inter-actions. Nature 1998;393:480–3.
   PubMed Web of Science ®Google Scholar
• Gerloni M, Rizzi M, Castiglioni P et al. T cell immunity usingtransgenic B lymphocytes. Proc Natl Acad Sci USA 2004;101:3892–7.
   PubMedGoogle Scholar
• Epstein MM, Di Rosa F, Jankovic D et al. Successful T cell priming in B cell-deficient mice. yExp Med 1995;182:915–22.
   Google Scholar
• On Z, Richter G, Schuler T et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998;4:627–30.
   Google Scholar
• Monach PA, Schreiber H, Rowley DA. CD4 ± and B lympho-cytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 1993;55:1356–61.
   PubMedGoogle Scholar
• Schultze JL, Michalak S, Seamon MJ et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. 7 Clin Invest 1997;100: 2757–65.
   Google Scholar
• Kimachi K, Croft M, Grey HM. The minimal number of antigen-major histocompatibility complex class II complexes required for activation of naive and primed T cells. Eur Immunol 1997;27:3310–7.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Gallimore A, Linkert S et al. Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. y Exp Med 1999;189:1521–30.
   PubMed Web of Science ®Google Scholar
• Zimmermann C, Prevost-Blondel A, Blaser C et al. Kinetics of the response of naive and memory CD8 T cells to antigen:similarities and differences. Eur y Immunol 1999;29:284–90.
   Google Scholar
• Dubey C, Croft M, Swain SL. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimu-latory signals. y Immunol 1996;157: 3280–9.
   Google Scholar
• Cho BK, Wang C, Sugawa S et al. Functional differences between memory and naive CD8 T cells. Proc Natl Acad Sci USA 1999;96:2976–81.
   Google Scholar
• Sallusto F, Lenig D, Forster R et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708–12.
   PubMed Web of Science ®Google Scholar
• van Kooten C, Rensink I, Pascual-Salcedo D et al. Monokine production by human T cells; IL-1 alpha production restricted to memory T cells. 7 Immunol 1991;146:2654–8.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Keilholz U, Rivoltini L et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 2000;60:4850–4.
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Letsch A, Thiel E et al. CD8 T-cell responsesto Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100:2132–7.
   PubMed Web of Science ®Google Scholar
• Gagliardi MC, De Petrillo G, Salemi S et al. Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro. Int Immunol 1995;7:1741–52.
   Google Scholar
• Lapointe R, Bellemare-Pelletier A, Housseau F et al. CD40-stimulated B lymphocytes pulsed with rumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836–43.
   PubMed Web of Science ®Google Scholar
• Kondo E, Topp MS, Kiem HP et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. y Immunol 2002;169:2164–71.
   Google Scholar
• Bergwelt-Baildon MS, Vonderheide RH, Maecker B et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002;99:3319–25.
   Google Scholar
• Sun Q, Burton RL, Dai LJ et al. B lymphoblastoid cell lines asefficient APC to elicit CD8± T cell responses against a cytomegalovirus antigen. y Immunol 2000;165:4105–11.
   Google Scholar
• Shankar P, Fabry J, Lieberman J. A simple method to selectivelyexpand HIV-1 specific cytotoxic T lymphocytes in vitro. Immunol Invest 1995;24:489–97.
   Web of Science ®Google Scholar
• Liu YN, Fuad S, Gehrz RC. Epstein- Barr virus-transformedlymphoblastoid cell lines as antigen-presenting cells and 'augmenting' cells for human CMV-specific Th clones. Cell Immunol 1987;108:64–75.
   Google Scholar
• Okamura T, Uluhan S, Rooney CM. Antigen-presenting capabilities of retrovirus-transduced T cell blasts. Blood 2003;102:285a.
   Google Scholar
• Atanackovic D, Matsuo M, Ritter E et al. Monitoring CD4± T cell responses against viral and rumor antigens using T cells as novel target APC. 7 Immunol Meth 2003;278: 57–66.
   Google Scholar
• Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant T x B cell hybrid. EMBO 1986;5:943–9.
   PubMed Web of Science ®Google Scholar
• Anderson K, Cresswell P, Gammon M et al. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. 7 Exp Med 1991;174:489–92.
   Google Scholar
• Britten CM, Meyer RG, Kreer T et al. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells forCD8( ) T lymphocytes in IFN-gamma ELISPOT assays. 7 Immunol Meth 2002;259:95–110.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Grube M, Brenchley JM et al. Functional leukemia-associated antigen-specific memory CD8± T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003;102:2892–900.
   PubMed Web of Science ®Google Scholar
• Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapyfor human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996;88:2450–7.
   PubMed Web of Science ®Google Scholar
• Mutis T, Blokland E, Kester M et al. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood 2002;100:547–52.
   PubMed Web of Science ®Google Scholar
• Amrolia PJ, Reid SD, Gao L, Goldman JM, Stauss HJ et al. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 2003;101:1007–14.
   PubMed Web of Science ®Google Scholar
• Storkus WJ, Alexander J, Payne JA et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci USA 1989;86:2361–4.
   PubMed Web of Science ®Google Scholar
• Hogan KT, Shimojo N, Walk SF et al. Mutations in the alpha 2helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide. y Exp Med 1988;168:725–36.
   Google Scholar
• Zhu MZ, Marshall J, Cole D et al. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 2000;6:24–33.
   PubMed Web of Science ®Google Scholar
• Correale P, Walmsley K, Zaremba S et al. Generation of humancytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. ylmmunol 1998;161:3186–94.
   PubMed Web of Science ®Google Scholar
• Sadovnikova E, Jopling LA, Soo KS et al. Generation of humantumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. EuryImmunol 1998;28:193–200.
   Google Scholar
• Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975;45:321–34.
   PubMed Web of Science ®Google Scholar
• Ortaldo JR, Oldham RK, Cannon GC et al. Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line. y Natl Cancer Inst 1977;59:77–82.
   PubMed Web of Science ®Google Scholar
• Maus MV, Thomas AK, Leonard DG et al. Ex vivo expansion ofpolyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002;20:143–8.
   PubMed Web of Science ®Google Scholar
• Thomas AK, Maus MV, Shalaby WS et al. A cell-based artificialantigen-presenting cell coated with anti-CD3 and CD28 anti-bodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol 2002;105:259–72.
   PubMed Web of Science ®Google Scholar
• Maus MV, Kovacs B, Kwok WW et al. Extensive replicative capacity of human central memory T cells. y Immunol 2004;172:6675–83.
   Google Scholar
• Shuford WW, Klussman K, Tritchler DD et al. 4-1BB costimulatory signals preferentially induce CD8± T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. y Exp Med 1997;186: 47–55.
   PubMed Web of Science ®Google Scholar
• Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28monoclonal antibodies to clone and expand human antigen-specific T cells. y Immunol Meth 1990;128:189–201.
   PubMed Web of Science ®Google Scholar
• Levine BL, Cotte J, Small CC et al. Large-scale production ofCD4± T cells from HIV-1-infected donors after CD3/CD28 costimulation. 7 Hematother 1998;7: 437— 48.
   Google Scholar
• Trickett A, Kwan YL. T cell stimulation and expansion using anti-CD3/CD28 beads. yImmunol Meth 2003;275:251–5.
   PubMed Web of Science ®Google Scholar
• Levine BL, Bernstein WB, Aronson NE et al. Adoptive transferof costimulated CD4± T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002;8:47–53.
   PubMed Web of Science ®Google Scholar
• Deeths MJ, Kedl RM, Mescher ME CD8± T cells become nonresponsive (anergic) following activation in the presence of costimulation. 7 Immunol 1999;163:102— 10.
   Google Scholar
• Deeths MJ, Mescher ME B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4± and CD8± T cells. Eur y Immunol 1997;27:598–608.
   PubMed Web of Science ®Google Scholar
• Oelke M, Maus MV, Didiano D et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003;9:619–24.
   PubMed Web of Science ®Google Scholar
• Maus MV, Riley JL, Kwok WW et al. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4± T cells. Clin Immunol 2003;106:16–22.
   PubMed Web of Science ®Google Scholar
• Oosten LE, Blokland E, Van Halteren AG et al. Artificial antigen-presenting constructs efficiently stimulate minor histo-compatibility antigen-specific cytotoxic T lymphocytes. Blood 2004;104:224— 6.
   Google Scholar
• Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34(± ) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451–8.
   PubMed Web of Science ®Google Scholar
• Palucka AK, Dhodapkar MV, Paczesny S et al. Single injection ofCD34± progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. y Immunother 2003;26:432 —9.
   Google Scholar
• Paczesny S, Banchereau J, Wittkowski KM et al. Expansion of melanoma-specific cytolytic CD8± T cell precursors in patients with metastatic melanoma vaccinated with CD34± progenitor-derived dendritic cells. yExp Med 2004;199:1503— 11.
   Google Scholar
• Hirano B, Butler MO, Freeman GJ et al. CD83:CD83L engagement plays an important role in the stimulation and expansion of antigen specific naive and memory CD8± T cells. Blood 2003;102:84a.
   Google Scholar
• Van der Bruggen P, Traversari C, Chamez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643–7.
   PubMed Web of Science ®Google Scholar
• Barratt-Boyes SM, Figdor CG. Current issues in delivering DCs for immunotherapy. Cytotherapy 2004;6:105–10.
   PubMed Web of Science ®Google Scholar
• Rice AM, Jones KL, Hart DN. DC preparations for therapy. Cytotherapy 2004;6:99— 104.
   Google Scholar
• Belz G, Smith C, Bharadwaj M et al. DCs as targets for vaccinedesign. Cytotherapy 2004;6:88— 98.
   Google Scholar
• Martin A, Magnusson RP, Kendler DL et al. Endogenous antigenpresentation by autoantigen-transfected Epstein— Barr virus-lymphoblastoid cells. I. Generation of human thyroid perox-idase-reactive T cells and their T cell receptor repertoire. y Clin Invest 1993;91:1567–74.
   Google Scholar
• Issekutz T, Chu E, Geha RS. Antigen presentation by human B cells: T cell proliferation induced by Epstein Barr virus B lymphoblastoid cells. y Immunol 1982;129: 1446— 50.
   Google Scholar
• Moosmann A, Khan N, Cobbold M et al. B cells immortalized bya mini-Epstein— Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood 2002;100:1755–64.
   Web of Science ®Google Scholar
• Montagna D, Schiavo R, Gibelli N et al. Ex vivo generation andexpansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. Int y Cancer 2004;110:76— 86.
   Google Scholar
• Bouet-Toussaint F, Patard JJ, Gervais A et al. Cytotoxic effectorcells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use. Cancer Immunol Immunother 2003;52:699— 707.
   Google Scholar
• Carlsson B, Cheng WS, Totterman TH et al. Ex vivo stimulationof cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. Br y Haematol 2003;121:428— 38.
   Google Scholar
• Hayashi T, Hideshima T, Akiyama M et al. Ex vivo induction ofmultiple myeloma-specific cytotoxic T lymphocytes. Blood 2003;102:1435–42.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Eder R, Kunz-Schughart LA et al. Large scale in vitro expansion of polyclonal human CD4 CD25high regula-tory T cells. Blood 2004; in press.
   Google Scholar
• Kim JV, Latouche JB, Riviere I et al. The ABCs of artificial antigen presentation. Nat Biotechnol 2004;22:403— 10.
   Google Scholar
• Oelke M, Schneck JP. HLA-Ig-based artificial antigen-present-ing cells: setting the terms of engagement. Clin Immunol 2004;110:243–51.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. 7 Clin Invest 2002;109:1519–26.
   PubMed Web of Science ®Google Scholar